Clinical Trial Results: A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rivoceranib in recurrent or metastatic adenoid cystic carcinoma has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma

Drugs mentioned

• Rivoceranib (rivoceranib)

Snippet

Sponsor: Elevar Therapeutics | Conditions: Adenoid Cystic Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2026-07-30